Wegovy Global Regulatory Status: FDA Approval, EMA Authorization, and Worldwide Access

FDA Approval Timeline and Regulatory Pathway

The FDA approved Wegovy on June 4, 2021, making it the first GLP-1 receptor agonist authorized specifically for chronic weight management at the 2.4 mg dose [1]. The approval came through a Biologics License Application (BLA 761177), reflecting semaglutide's peptide-based structure. This was a significant regulatory distinction. Novo Nordisk had already secured approval for semaglutide at lower doses under the brand name Ozempic for type 2 diabetes, but the obesity indication required a separate clinical development program and a dedicated BLA submission.

The FDA's decision rested primarily on the STEP clinical trial program, a series of four Phase 3 trials enrolling more than 4,500 participants across multiple countries [1]. STEP-1, the key trial (N=1,961), demonstrated that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks compared to 2.4% with placebo [1]. The FDA granted priority review based on the magnitude of weight loss observed, which exceeded outcomes from previously approved anti-obesity medications by a substantial margin.

Wegovy's approval carried specific labeling requirements from the outset. The FDA mandated a Risk Evaluation and Mitigation Strategy (REMS) communication plan and required a boxed warning regarding the risk of thyroid C-cell tumors, based on rodent carcinogenicity studies with GLP-1 receptor agonists [2]. The label also listed medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) as contraindications.

The SELECT Trial and Cardiovascular Label Expansion

On March 8, 2024, the FDA approved a supplemental indication for Wegovy to reduce the risk of major adverse cardiovascular events (MACE) in adults with established cardiovascular disease and either obesity or overweight [3]. This made Wegovy the first anti-obesity medication to carry a cardiovascular risk reduction claim on its label.

The SELECT trial (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) randomized 17,604 adults aged 45 years or older with pre-existing cardiovascular disease and BMI ≥27 (without diabetes) to semaglutide 2.4 mg or placebo [3]. Over a mean follow-up of 39.8 months, semaglutide reduced the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke by 20% (hazard ratio 0.80; 95% CI 0.72 to 0.90; P<0.001) [3].

The cardiovascular benefit appeared early. Kaplan-Meier curves separated within the first year of treatment. Dr. A. Michael Lincoff, the trial's lead investigator at the Cleveland Clinic, stated: "The cardiovascular benefits of semaglutide were consistent across subgroups regardless of baseline BMI, age, sex, or race" [3]. This finding shifted the regulatory and clinical conversation around GLP-1 agonists from weight loss alone to cardiometabolic risk management.

The American Heart Association and the American College of Cardiology have since updated clinical guidance to reflect this expanded indication, recognizing semaglutide 2.4 mg as a treatment option for secondary cardiovascular prevention in patients with obesity [4].

EMA Authorization and European Market Access

The European Medicines Agency (EMA) granted centralized marketing authorization for Wegovy on January 6, 2022, covering all 27 EU member states plus Iceland, Liechtenstein, and Norway [5]. The Committee for Medicinal Products for Human Use (CHMP) based its positive opinion on the same STEP trial program that supported the FDA approval, though the European regulatory pathway involved additional evaluation of cost-effectiveness by individual national health technology assessment (HTA) bodies.

European access has been uneven. Germany's Federal Joint Committee (G-BA) classified Wegovy as having "considerable additional benefit" for patients with BMI ≥35 and at least one weight-related comorbidity, which cleared a path for statutory health insurance coverage. The UK's Medicines and Healthcare Products Regulatory Agency (MHRA) authorized Wegovy separately from the EMA process in September 2023, with the National Institute for Health and Care Excellence (NICE) subsequently issuing positive technology appraisal guidance recommending NHS funding under specific BMI and comorbidity criteria [6].

France, by contrast, delayed reimbursement decisions, citing the need for longer-term safety data and real-world cost projections. The Haute Autorité de Santé (HAS) completed its evaluation in late 2024. Each country's pricing and reimbursement timeline has created a fragmented access picture across Europe, even though the underlying marketing authorization is uniform.

The EMA also required Novo Nordisk to conduct post-authorization safety studies (PASS) monitoring long-term cardiovascular outcomes, thyroid safety signals, and potential effects on bone mineral density in European populations [5]. These studies remain ongoing.

Pediatric Approval: Adolescents Aged 12 and Older

The FDA expanded Wegovy's indication to include adolescents aged 12 to 17 with obesity (defined as initial BMI at the 95th percentile or above for age and sex) in December 2022 [7]. This approval was based on the STEP TEENS trial (N=201), which showed a 16.1% reduction in BMI from baseline versus a 0.6% increase with placebo over 68 weeks [8].

The pediatric approval was notable for several reasons. It marked one of the few anti-obesity pharmacotherapies available for adolescents, a population with limited treatment options beyond lifestyle intervention and bariatric surgery. The American Academy of Pediatrics (AAP) had published updated clinical practice guidelines in January 2023 recommending pharmacotherapy as part of a comprehensive approach to childhood obesity, aligning with the expanded availability of Wegovy [9].

The EMA followed with a similar pediatric indication in 2023, though uptake across EU member states has been slower due to separate pediatric reimbursement pathways and the particular caution that HTA bodies apply to long-term pharmacotherapy in younger populations. In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) has not yet approved a pediatric indication for semaglutide 2.4 mg.

Current FDA Label: Indications, Dosing, and Warnings

The current Wegovy prescribing information lists two approved indications [2]:

1. Chronic weight management in adults with BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, or dyslipidemia), as an adjunct to reduced-calorie diet and increased physical activity.
2. Reduction of cardiovascular risk (cardiovascular death, nonfatal MI, or nonfatal stroke) in adults with established cardiovascular disease and either obesity or overweight.

Dosing follows a five-step escalation schedule. Patients begin at 0.25 mg subcutaneously once weekly for four weeks, increasing monthly through 0.5 mg, 1.0 mg, and 1.7 mg before reaching the maintenance dose of 2.4 mg at week 17. The escalation protocol reduces gastrointestinal side effects, which are the most common adverse reactions.

The label carries a boxed warning for thyroid C-cell tumors based on findings in rodents exposed to semaglutide. Contraindications include personal or family history of MTC, MEN 2, and known hypersensitivity to semaglutide or any excipient [2]. Warnings and precautions cover acute pancreatitis (observed in 0.2% of STEP trial participants versus 0.1% on placebo), gallbladder-related events (cholelithiasis occurred in 1.6% vs. 0.7%), acute kidney injury (primarily from dehydration due to GI symptoms), suicidal behavior and ideation, and diabetic retinopathy complications in patients with type 2 diabetes.

The label specifically states that Wegovy has not been studied in patients with a history of pancreatitis and should be used with caution in this population [2]. Concurrent use with other semaglutide-containing products (Ozempic, Rybelsus) or other GLP-1 receptor agonists is not recommended.

Post-Market Safety Surveillance

The FDA monitors Wegovy through multiple post-market surveillance mechanisms. The FDA Sentinel System, a distributed data network covering over 100 million patients across participating health plans, provides active surveillance for pre-specified safety signals [10].

Key areas of ongoing monitoring include thyroid C-cell signals, pancreatitis, gallbladder disease, and suicidality. The FDA issued a safety communication in January 2024 noting that its review of post-market reports and clinical trial data had not found a causal association between GLP-1 receptor agonists and suicidal thoughts or actions, though monitoring continues [10].

Novo Nordisk is also conducting post-marketing requirement (PMR) studies mandated by the FDA at the time of approval. These include a long-term rodent carcinogenicity study with a focus on thyroid C-cell pathology, as well as real-world observational studies assessing outcomes in populations underrepresented in clinical trials, including patients with severe renal impairment and those over age 75 [2].

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) conducts parallel monitoring. In mid-2023, PRAC reviewed a signal for suicidal ideation associated with GLP-1 receptor agonists more broadly, including liraglutide and semaglutide. The committee concluded that available evidence did not support a causal relationship but recommended continued monitoring and updated product information to reflect the ongoing evaluation [5]. A large Nordic observational cohort study published in JAMA Internal Medicine (N=over 300,000 GLP-1 RA users) found no increased risk of suicidal behavior compared to matched non-users, providing further reassurance [11].

Regulatory Status in Asia-Pacific Markets

Japan's PMDA approved semaglutide 2.4 mg for chronic weight management in March 2024, making Japan one of the last major pharmaceutical markets to grant approval [12]. The Japanese indication applies to adults with BMI ≥35 or BMI ≥27 with at least two obesity-related comorbidities, reflecting the different BMI thresholds used in Japanese clinical practice given the higher metabolic risk at lower BMI levels in East Asian populations.

Australia's Therapeutic Goods Administration (TGA) approved Wegovy in October 2022, and it was listed on the Pharmaceutical Benefits Scheme (PBS) in a restricted category in 2024. South Korea's Ministry of Food and Drug Safety (MFDS) approved semaglutide 2.4 mg in early 2023.

Access in these markets has been shaped by supply allocation decisions by Novo Nordisk, which prioritized existing patients and markets where the drug was already being prescribed to maintain continuity of care during global shortages.

Supply Constraints and Their Regulatory Implications

Demand for Wegovy consistently exceeded manufacturing capacity from 2022 through most of 2024. Novo Nordisk voluntarily suspended the starter dose pens (0.25 mg, 0.5 mg, and 1.0 mg) from the US market for new patients in late 2022 to ensure continuity for patients already titrating [12]. These doses returned to supply by early 2024.

The supply shortage had regulatory consequences. The FDA placed semaglutide injection on its official Drug Shortages list, which under federal law permitted compounding pharmacies to produce copies of the active ingredient for individual patient use [13]. Compounded semaglutide, prepared from bulk active pharmaceutical ingredient, became widely available through 503A and 503B pharmacies.

When Novo Nordisk resolved its supply constraints, the FDA removed semaglutide injection from the shortage list in late 2024, triggering legal and regulatory disputes about whether compounding pharmacies could continue production [13]. The FDA's position was that once the shortage ended, the compounding exemption no longer applied. Multiple compounding pharmacy organizations challenged this in federal court, with litigation ongoing.

This regulatory gray area has created a two-track market: branded Wegovy with full FDA oversight and quality controls, and compounded semaglutide with variable quality assurance depending on the compounding facility. The FDA issued warning letters to several compounding pharmacies in 2024 and 2025 for manufacturing violations, including potency inconsistencies and sterility failures [13].

Intellectual Property and Biosimilar Horizon

Novo Nordisk holds multiple patents on semaglutide formulation, delivery device, and dose-escalation protocols. The core compound patent extends through 2032 in the US and EU, though individual patent claims vary by jurisdiction. No biosimilar applications for semaglutide 2.4 mg have been accepted for review by either the FDA or EMA as of May 2026.

The 12-year biologics exclusivity period under the Biologics Price Competition and Innovation Act (BPCIA) runs from the date of BLA approval (June 2021), meaning the earliest a biosimilar could be approved based on exclusivity alone is June 2033 [14]. Patent litigation could extend or shorten practical exclusivity depending on the outcome of inter partes review and any paragraph IV-equivalent challenges for biologics.

Several generic and biosimilar manufacturers, including Teva, Biocon, and multiple Chinese pharmaceutical companies, have publicly disclosed early-stage development programs for semaglutide biosimilars. None have entered Phase 3 trials for the 2.4 mg obesity dose as of this writing.

Ongoing Regulatory Reviews and Pipeline Expansions

Novo Nordisk submitted a supplemental BLA to the FDA in late 2025 seeking expanded labeling for Wegovy based on new data from the STEP-HFpEF and STEP-HFpEF DM trials, which demonstrated improvements in heart failure symptoms and physical limitations in patients with heart failure with preserved ejection fraction (HFpEF) and obesity [15]. The STEP-HFpEF trial (N=529) showed a mean 7.8-point improvement in Kansas City Cardiomyopathy Questionnaire score with semaglutide versus 1.4 points with placebo [15].

A potential label expansion for obstructive sleep apnea (OSA) is also under FDA review, based on the STEP-OSA trial program, which reported reductions in apnea-hypopnea index of approximately 40% in patients with moderate-to-severe OSA treated with semaglutide 2.4 mg.

The oral semaglutide program at higher doses (25 mg and 50 mg) represents a separate regulatory track. Novo Nordisk's Phase 3 OASIS-1 trial of oral semaglutide 50 mg showed 15.1% body weight reduction at 68 weeks, comparable to injectable Wegovy. A new BLA for oral semaglutide for obesity is expected in 2026.

Clinicians prescribing Wegovy should verify current labeling at Drugs@FDA before initiating treatment, as supplemental approvals may update contraindications, warnings, or approved populations between guideline revision cycles [2].